Avalo Therapeutics, Inc.: director Kevin Robert Lind received 1,352 shares

What happened Kevin Robert Lind, director, was granted options for 1,352 underlying shares at an exercise price of $12.29 per share, for a reported total of $16,616 on Sep 30, 2026.

Key details

• Transaction date and price: Sep 30, 2026 — grant (A) of options for 1,352 shares at $12.29 per share.
• Transaction type: derivative grant (code A).
• Shares owned after the transaction: not reported in the Form 4 provided here.
• Footnotes: F1 — the options were granted on Sep 30, 2026 and are 100% vested; F2 — the options were issued pursuant to the issuer's amended and restated non-employee director compensation plan in lieu of board fees.
• Filing date: Oct 2, 2026 (accession 0001677036-26-000009).

Why it may matter This filing reports a grant of options to a director (a derivative award), not a market sale or purchase. The filing does not show why the insider traded or why the company acted.